Departments - The ASCO Post

Advertisement

Advertisement

Error loading Partial View script (file: ~/Views/MacroPartials/TAP All Departments.cshtml)

Advertisement

Advertisement

Jun

26

Today In Oncology

Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders

Comparison of Combination Dosing Schedules of Neoadjuvant Ipilimumab/Nivolumab in Macroscopic Stage III Melanoma

Are Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma Common?

Immune Response to HPV16-Driven Tumorigenesis May Be Detectable Before Clinical Diagnosis of Oropharyngeal Squamous Cell Carcinoma

Study Finds Primary Care Providers Are Engaged in Cancer Survivorship Care but Report Barriers to Optimal Care Delivery

;

Advertisement

Most Read Stories

2019 ASCO: 3-Year Outcomes in the KRISTINE Trial on Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab in HER2-Positive Breast Cancer

Fallopian Tube Removal May Protect Premenopausal Women at High Risk for Ovarian Cancer From Some Surgical Side Effects

Rate and Outcome of Late Relapses in Patients With DLBCL Treated With Immunochemotherapy

ENGOT-OV16/NOVA: Niraparib Maintenance According to Complete or Partial Response to Platinum Chemotherapy for Recurrent Ovarian Cancer

EHA 2019: CLL12 Trial Investigates Ibrutinib in Previously Untreated, Asymptomatic Early-Stage CLL

Most Viewed Videos

Matthew A. Powell, MD, and Don S. Dizon, MD, on Uterine or Ovarian Cancer: Paclitaxel Plus Carboplatin vs Ifosfamide in Chemotherapy-Naive Patients

Miriam Knoll, MD, and Zachery Reichert, MD, PhD, on Prostate Cancer: Focal Radiation for Oligometastatic Castration-Resistant Disease

Richard Pazdur, MD, on the Launch of Project Facilitate

Luis G. Paz-Ares, MD, PhD, on Small Cell Lung Cancer: Efficacy and Safety of Lurbinectedin

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

© 2019 HSP News Service, L.L.C.